PRPO
Precipio, Inc.
Healthcare — Diagnostics & Research
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
None
$22.73
$-0.95 (-4.01%)
Price History
52-Week Range
Sign in to add PRPO to a watchlist or set price alerts.
Fundamentals
| Market Cap | $44.56M |
| P/E Ratio (TTM) | - |
| Forward P/E | 63.92 |
| EPS (TTM) | $-0.45 |
| Dividend Yield | - |
| Profit Margin | -3.57% |
| Revenue Growth | 36.20% |
| ROE | -7.13% |
| Debt/Equity | 24.65 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 71.7 |
| Beta | 1.30 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $33.63 |
| 52-Week Low | $11.23 |
| 50-Day Avg | $25.60 |
| 200-Day Avg | $23.79 |
| Avg Volume | 110.9K |
| Volume | 236.3K |
Performance Analysis
BEARISHPRPO is flashing more cautionary signals — investors should monitor closely.
~
Trading at 51% of its 52-week range.
-
RSI at 71.7 indicates overbought conditions — a pullback may be due.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Strong revenue growth of 36.2% year-over-year.
-
Operating at a loss with -3.6% margin.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:27 UTC
Back to Screener Export Report